应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00719 山东新华制药股份
未开盘 11-17 16:08:13
5.045
-0.100
-1.94%
最高
5.150
最低
5.045
成交量
66.20万
今开
5.150
昨收
5.145
日振幅
2.04%
总市值
35.16亿
流通市值
9.84亿
总股本
6.97亿
成交额
336.65万
换手率
0.34%
流通股本
1.95亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
山东新华制药(00719)公布临时股东会决议 刘伟民接任董事长
公告速递 · 11-10
山东新华制药(00719)公布临时股东会决议 刘伟民接任董事长
山东新华制药股份(00719)公布董事会及专门委员会成员构成
公告速递 · 11-10
山东新华制药股份(00719)公布董事会及专门委员会成员构成
山东新华制药股份(00719.HK):刘伟民已获选为第十一届董事会董事长
智通财经 · 11-10
山东新华制药股份(00719.HK):刘伟民已获选为第十一届董事会董事长
山东新华制药(00719)取得酮咯酸氨丁三醇注射液注册证书
公告速递 · 11-06
山东新华制药(00719)取得酮咯酸氨丁三醇注射液注册证书
山东新华制药股份(00719)获得酮咯酸氨丁三醇注射液药品注册证书
智通财经 · 11-06
山东新华制药股份(00719)获得酮咯酸氨丁三醇注射液药品注册证书
山东新华制药股份10月股份变动月报表发布,股本维持不变
公告速递 · 11-02
山东新华制药股份10月股份变动月报表发布,股本维持不变
山东新华制药股份(00719)前三季度净利1.95亿元,同比下降23.88%
公告速递 · 10-28
山东新华制药股份(00719)前三季度净利1.95亿元,同比下降23.88%
山东新华制药(00719)公布前三季度业绩:营收60.61亿元,同比降10.38%
公告速递 · 10-28
山东新华制药(00719)公布前三季度业绩:营收60.61亿元,同比降10.38%
山东新华制药股份(00719)董事会批准2026年第三季度报告并授权办理港交所“联讯通”注册
公告速递 · 10-28
山东新华制药股份(00719)董事会批准2026年第三季度报告并授权办理港交所“联讯通”注册
山东新华制药股份(00719)前三季度归母净利润1.95亿元 同比减少23.88%
智通财经 · 10-28
山东新华制药股份(00719)前三季度归母净利润1.95亿元 同比减少23.88%
山东新华制药(00719)尼莫地平片获一致性评价 强化市场竞争力
公告速递 · 10-19
山东新华制药(00719)尼莫地平片获一致性评价 强化市场竞争力
山东新华制药(00719)将于11月10日召开临时股东大会 审议委任刘伟民为执行董事
公告速递 · 10-16
山东新华制药(00719)将于11月10日召开临时股东大会 审议委任刘伟民为执行董事
山东新华制药(00719)公告10月28日召开董事会 审议截至9月30日止九个月未审计业绩
公告速递 · 10-14
山东新华制药(00719)公告10月28日召开董事会 审议截至9月30日止九个月未审计业绩
山东新华制药股份(00719)董事会秘书曹长求拟减持不超过8.33万股股份
智通财经 · 10-13
山东新华制药股份(00719)董事会秘书曹长求拟减持不超过8.33万股股份
山东新华制药股份(00719)披露高管拟减持不超8.33万股 占总股本0.012%
公告速递 · 10-13
山东新华制药股份(00719)披露高管拟减持不超8.33万股 占总股本0.012%
山东新华制药(00719)拟委任刘伟民为执行董事 月薪4.33万元
公告速递 · 10-09
山东新华制药(00719)拟委任刘伟民为执行董事 月薪4.33万元
山东新华制药股份(00719):刘伟民获委任为执行董事的候选人
智通财经 · 10-09
山东新华制药股份(00719):刘伟民获委任为执行董事的候选人
山东新华制药(00719)取得沙库巴曲缬沙坦钠片注册证书,切入年销78亿元市场
公告速递 · 10-08
山东新华制药(00719)取得沙库巴曲缬沙坦钠片注册证书,切入年销78亿元市场
山东新华制药股份9月股份变动月报表:股本维持稳定
公告速递 · 10-07
山东新华制药股份9月股份变动月报表:股本维持稳定
山东新华制药(00719)副总经理刘雪松辞任
公告速递 · 09-29
山东新华制药(00719)副总经理刘雪松辞任
加载更多
公司概况
公司名称:
山东新华制药股份
所属市场:
SEHK
上市日期:
--
主营业务:
山东新华制药股份有限公司是一家主要从事化学原料药、制剂及化工产品的开发、制造和销售的中国公司。该公司运营三个分部。化学原料药分部主要从事咖啡因系列、布洛芬系列、阿司匹林系列、多巴系列、巴比妥系列及吡哌酸等解热镇痛类原料药的开发、制造及销售。制剂分部主要从事吡哌酸片、安痛定及尼莫地平片等片剂、针剂及胶囊剂等制剂的开发、制造及销售。医药中间体及其他产品分部主要从事医药中间体及其他产品的开发、制造及销售。该公司主要在中国国内市场及美洲和欧洲等海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":5.045,"timestamp":1794902893169,"preClose":5.145,"halted":0,"volume":662000,"delay":0,"changeRate":-0.019436345966958143,"floatShares":195000000,"shares":697000000,"eps":0.49436150930960615,"marketStatus":"未开盘","change":-0.1,"latestTime":"11-17 16:08:13","open":5.15,"high":5.15,"low":5.045,"amount":3366460,"amplitude":0.020408,"askPrice":5.045,"askSize":4000,"bidPrice":5.04,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":0.3885187101664195,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794965400000},"marketStatusCode":0,"adr":0,"listingDate":851961600000,"exchange":"SEHK","adjPreClose":5.145,"dividendRate":0.034984,"openAndCloseTimeList":[[1794879000000,1794888000000],[1794891600000,1794902400000]],"volumeRatio":1.5383900353225506,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":12.03,"timestamp":1794898800000,"preClose":12.19,"halted":0,"volume":6091400,"delay":0,"premium":"-64.37"}},"requestUrl":"/m/hq/s/00719","defaultTab":"news","newsList":[{"id":"1136998641","title":"山东新华制药(00719)公布临时股东会决议 刘伟民接任董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=1136998641","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136998641?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:32","pubTimestamp":1794303152,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司(00719)11月11日公告称,公司于2026年11月10日在山东省淄博市高新区鲁泰大道1号公司会议室召开临时股东会,并就多项事项进行表决。会议以现场及网络投票方式进行,出席会议的A股股东1名、H股股东1名,以及通过网络投票的A股股东471名。参会股东共代表248,029,077股表决权股份,占公司已发行股份总数的35.60%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140855535","title":"山东新华制药股份(00719)公布董事会及专门委员会成员构成","url":"https://stock-news.laohu8.com/highlight/detail?id=1140855535","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140855535?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:30","pubTimestamp":1794303057,"startTime":"0","endTime":"0","summary":"2026年11月10日,山东新华制药股份有限公司在中国淄博发布公告,披露董事会最新成员名单及其在四大专门委员会中的职务分配。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682636075","title":"山东新华制药股份(00719.HK):刘伟民已获选为第十一届董事会董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2682636075","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682636075?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:24","pubTimestamp":1794302696,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1191","00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122681683","title":"山东新华制药(00719)取得酮咯酸氨丁三醇注射液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1122681683","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122681683?lang=zh_cn&edition=full","pubTime":"2026-11-06 16:52","pubTimestamp":1793955132,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司11月6日公告称,公司已于2026年11月6日收到国家药品监督管理局签发的酮咯酸氨丁三醇注射液《药品注册证书》。本品为注射剂,规格1ml:30mg,注册分类为化学药品3类,药品批准文号为“国药准字H20266508”。根据相关统计数据,2025年中国公立医疗机构酮咯酸氨丁三醇注射液销售额约为人民币2.3亿元。新华制药于2025年2月向国家药品监督管理局药品审评中心递交该产品的上市许可注册申报资料并获得受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681569458","title":"山东新华制药股份(00719)获得酮咯酸氨丁三醇注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2681569458","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681569458?lang=zh_cn&edition=full","pubTime":"2026-11-06 16:51","pubTimestamp":1793955115,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,公司收到国家药品监督管理局核准签发的酮咯酸氨丁三醇注射液《药品注册证书》。本品适用于成人需要阿片水平镇痛的中重度急性疼痛的短期治疗(不超过5天),通常用于手术后镇痛。本品属于《国家基本医疗保险、工伤保险和生育保险药品目录(2025年)》乙类品种。根据相关统计数据,2025年中国公立医疗机构酮咯酸氨丁三醇注射液销售额约为人民币2.3亿元。新华制药的酮咯酸氨丁三醇注射液于2026年11月取得药品注册证书,有利于丰富公司镇痛类产品系列,提高公司市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山东新华制药股份(00719)获得酮咯酸氨丁三醇注射液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171919049","title":"山东新华制药股份10月股份变动月报表发布,股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1171919049","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171919049?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:05","pubTimestamp":1793577954,"startTime":"0","endTime":"0","summary":"2026年11月2日,山东新华制药股份有限公司公布截至2026年10月31日的股份变动月报表。公告显示,公司在报告期内的注册股本合计为人民币696,683,435元,较上月保持不变。根据月报,公司普通股H股数量为195,000,000股,普通股A股数量为501,683,435股,均与上月底持平,报告期内未出现新增发行、回购、注销或库藏股活动。同时,公司披露2021年A股股票期权计划所涉及的1,155,000份期权数量未发生行使或失效,期末结存不变,未给公司已发行股份总数带来增减变化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188253730","title":"山东新华制药股份(00719)前三季度净利1.95亿元,同比下降23.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188253730","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188253730?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:51","pubTimestamp":1793177501,"startTime":"0","endTime":"0","summary":"2026年10月28日,山东新华制药股份有限公司披露2026年第三季度报告。报告期内公司主要财务数据如下:。营业收入17.03亿元,同比下降19.80%。扣除非经常性损益后的归属于上市公司股东的净利润3,958.30万元,同比上升40.38%。基本每股收益0.07元,同比提高40.00%。营业收入60.61亿元,同比下降10.38%。归属于上市公司股东的净利润1.95亿元,同比下降23.88%。经营活动产生的现金流量净额1.82亿元,同比下降43.62%。基本每股收益0.28元,同比下降24.32%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106446999","title":"山东新华制药(00719)公布前三季度业绩:营收60.61亿元,同比降10.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106446999","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106446999?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:51","pubTimestamp":1793177498,"startTime":"0","endTime":"0","summary":"2026年10月28日,山东新华制药股份有限公司披露截至2026年9月30日止九个月未经审计的综合业绩。营业收入为60.61亿元,较上年同期的67.63亿元下降10.38%。归属于上市公司股东的净利润为1.95亿元,同比下降23.88%。基本及稀释每股收益均为0.28元,上年同期均为0.37元,同比下降24.32%。加权平均净资产收益率为3.67%,较上年同期下降1.34个百分点。经营活动产生的现金流量净额为1.82亿元,同比下降43.62%。截至2026年9月30日,集团总资产为88.07亿元,较2025年末减少4.12%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148754042","title":"山东新华制药股份(00719)董事会批准2026年第三季度报告并授权办理港交所“联讯通”注册","url":"https://stock-news.laohu8.com/highlight/detail?id=1148754042","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148754042?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:51","pubTimestamp":1793177475,"startTime":"0","endTime":"0","summary":"\\n\\n2. 会议以8票同意、0票反对、0票弃权审议通过《关于提请董事会授权办理香港联交所联讯通平台注册等相关事项的议案》。董事会同意接纳《香港联交所联讯通条款及细则》,并授权指定人士办理联讯通账户注册、提交相关文件及开展后续工作。\\n\\n公司表示,董事会授权任何一名董事或授权代表代表公司完成联讯通注册及文件递交等全部事宜。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678451467","title":"山东新华制药股份(00719)前三季度归母净利润1.95亿元 同比减少23.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678451467","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678451467?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:48","pubTimestamp":1793177294,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布截至2026年9月30日止九个月业绩,营业收入60.61亿元(人民币,下同),同比减少10.38%;归属于上市公司股东的净利润1.95亿元,同比减少23.88%;基本每股收益0.28元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180015998","title":"山东新华制药(00719)尼莫地平片获一致性评价 强化市场竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=1180015998","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180015998?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:12","pubTimestamp":1792404756,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司10月19日披露,其尼莫地平片已获国家药品监督管理局签发的《药品补充申请批准通知书》,通过仿制药质量和疗效一致性评价。公告显示,新华制药于2025年7月向国家药监局药品审评中心提交尼莫地平片一致性评价申报材料,并于2026年10月获批。根据公告援引的统计数据,2025年中国公立医疗机构尼莫地平片销售额约为1.3亿元。公司认为,通过一致性评价有助于提升该产品的市场竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192758043","title":"山东新华制药(00719)将于11月10日召开临时股东大会 审议委任刘伟民为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1192758043","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192758043?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:45","pubTimestamp":1792140341,"startTime":"0","endTime":"0","summary":"- 参会资格:截至11月3日在香港中央证券登记有限公司及中国证券登记结算深圳分公司名册上的股东,以及公司董事、高管","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135125932","title":"山东新华制药(00719)公告10月28日召开董事会 审议截至9月30日止九个月未审计业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1135125932","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135125932?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:36","pubTimestamp":1791966979,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司(00719)10月14日发布公告称,董事会已发出会议通知,定于2026年10月28日(星期三)上午9时30分在中国山东省淄博市高新区鲁泰大道1号公司会议室召开董事会会议。此次会议的主要议程包括:\n1. 审议并批准公司及其附属公司截至2026年9月30日止九个月的未审计业绩;\n2. 处理任何其他相关事宜(如适用)。\n公告同时披露,当前董事会成员包括:执行董事贺同庆(董事长)、徐文辉、侯宁;独立非执行董事潘广成、朱建伟、凌沛学、张菁菁;非执行董事张成勇。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675337173","title":"山东新华制药股份(00719)董事会秘书曹长求拟减持不超过8.33万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2675337173","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675337173?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:27","pubTimestamp":1791883670,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)公布,公司于近日收到公司董事会秘书曹长求先生发送的《股份减持计划告知函》,其计划在本公告发布之日起的 15 个交易日之后的 3 个月内以集中竞价方式减持公司股份不超过8.33万股,占公司总股本的 0.012%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177906139","title":"山东新华制药股份(00719)披露高管拟减持不超8.33万股 占总股本0.012%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177906139","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177906139?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:22","pubTimestamp":1791883326,"startTime":"0","endTime":"0","summary":"曹长求目前持有公司A股333,200股,占公司总股本的0.048%。根据减持计划,其拟于本公告披露之日起15个交易日后的3个月内,以集中竞价方式减持不超过83,300股,占公司总股本的0.012%。公告指出,本次减持符合《上市公司股东减持股份管理暂行办法》等相关法规的规定,减持实施不会导致公司控制权发生变更,也不会对公司治理结构、股权结构及持续经营产生重大影响。公司承诺在减持期间严格履行信息披露义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174300690","title":"山东新华制药(00719)拟委任刘伟民为执行董事 月薪4.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174300690","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174300690?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:42","pubTimestamp":1791538952,"startTime":"0","endTime":"0","summary":"10月9日,山东新华制药股份有限公司发布公告称,董事会已决议提名刘伟民为执行董事候选人。该任命尚需提交预计于2026年11月10日前后召开的临时股东大会,并以普通决议案形式获得股东批准后方可生效。根据公告,刘伟民的任期拟自股东大会批准当日起至公司第十一届董事会届满之日止。经股东批准后,公司将与刘伟民签订服务合约,月度基础薪酬建议为人民币4.33万元。2026年9月起,刘伟民加入山东新华制药股份有限公司并担任党委书记。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674130830","title":"山东新华制药股份(00719):刘伟民获委任为执行董事的候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2674130830","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674130830?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:37","pubTimestamp":1791538675,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,董事会已议决建议刘伟民先生(刘先生)为获委任为执行董事的候选人,惟须待本公司的股东在将于2026年11月10日或前后举行的本公司临时股东会上批准后方可作实,此乃基于董事会提名委员会提出的推荐。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","00719","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131712876","title":"山东新华制药(00719)取得沙库巴曲缬沙坦钠片注册证书,切入年销78亿元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1131712876","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131712876?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:56","pubTimestamp":1791449769,"startTime":"0","endTime":"0","summary":"2026年10月8日,山东新华制药股份有限公司公告称,已于2026年10月收到国家药品监督管理局核准签发的沙库巴曲缬沙坦钠片《药品注册证书》,产品规格为沙库巴曲缬沙坦计50mg,注册分类为化学药品4类,剂型为片剂,药品属性为处方药。新华制药于2025年4月向国家药品监督管理局药品审评中心递交上市许可注册申报,并于2026年10月获批准注册。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166169986","title":"山东新华制药股份9月股份变动月报表:股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1166169986","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166169986?lang=zh_cn&edition=full","pubTime":"2026-10-07 14:35","pubTimestamp":1791354935,"startTime":"0","endTime":"0","summary":"山东新华制药股份于2026年10月7日发布2026年9月股份变动月报表。报告期为2026年9月1日至9月30日,公司法定注册股本及已发行股份情况维持不变。公司法定注册股本方面,普通股H股于上月底结存195,000,000股、A股于上月底结存501,683,435股,报告期内未发生增减变动。本月底公司法定注册股本总额仍保持在人民币696,683,435元。截至本月底,未有新增行权或由库存转让的股份数目,上述期权在报告期内无变动。本次公告由公司秘书曹长求签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129190178","title":"山东新华制药(00719)副总经理刘雪松辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1129190178","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129190178?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:56","pubTimestamp":1790672187,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司9月29日公告称,公司董事会于2026年9月29日收到副总经理刘雪松的书面辞职报告。刘雪松因工作变动原因,辞去公司副总经理及在公司担任的其他一切职务,辞职自送达董事会之日起生效。\\n\\n公告显示,刘雪松在任职期间与董事会无意见分歧,亦不存在需提请股东注意的其他事项。\\n\\n截至公告披露日,刘雪松持有公司A股223,100股。\\n\\n董事会对刘雪松先生在任期间所作出的贡献表示感谢。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xhzy.com","stockEarnings":[{"period":"1week","weight":-0.0692},{"period":"1month","weight":-0.0819},{"period":"3month","weight":-0.1478},{"period":"6month","weight":-0.166},{"period":"1year","weight":-0.2733},{"period":"ytd","weight":-0.2115}],"compareEarnings":[{"period":"1week","weight":-0.0427},{"period":"1month","weight":-0.0281},{"period":"3month","weight":-0.0779},{"period":"6month","weight":-0.074},{"period":"1year","weight":-0.109},{"period":"ytd","weight":-0.0828}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东新华制药股份有限公司是一家主要从事化学原料药、制剂及化工产品的开发、制造和销售的中国公司。该公司运营三个分部。化学原料药分部主要从事咖啡因系列、布洛芬系列、阿司匹林系列、多巴系列、巴比妥系列及吡哌酸等解热镇痛类原料药的开发、制造及销售。制剂分部主要从事吡哌酸片、安痛定及尼莫地平片等片剂、针剂及胶囊剂等制剂的开发、制造及销售。医药中间体及其他产品分部主要从事医药中间体及其他产品的开发、制造及销售。该公司主要在中国国内市场及美洲和欧洲等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.012135},{"month":2,"riseRate":0.766667,"avgChangeRate":0.099902},{"month":3,"riseRate":0.433333,"avgChangeRate":-0.007748},{"month":4,"riseRate":0.7,"avgChangeRate":0.100629},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.000855},{"month":6,"riseRate":0.433333,"avgChangeRate":-0.005711},{"month":7,"riseRate":0.6,"avgChangeRate":0.01986},{"month":8,"riseRate":0.275862,"avgChangeRate":-0.043444},{"month":9,"riseRate":0.37931,"avgChangeRate":-0.016386},{"month":10,"riseRate":0.433333,"avgChangeRate":0.006052},{"month":11,"riseRate":0.533333,"avgChangeRate":0.009891},{"month":12,"riseRate":0.586207,"avgChangeRate":0.023647}],"exchange":"SEHK","name":"山东新华制药股份","nameEN":"SHANDONG XINHUA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"山东新华制药股份,00719,山东新华制药股份股票,山东新华制药股份股票老虎,山东新华制药股份股票老虎国际,山东新华制药股份行情,山东新华制药股份股票行情,山东新华制药股份股价,山东新华制药股份股市,山东新华制药股份股票价格,山东新华制药股份股票交易,山东新华制药股份股票购买,山东新华制药股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}